Keryx Looks To Release Top-Line Sulonex Phase III Data Early Next Year
This article was originally published in The Pink Sheet Daily
Executive Summary
A 2008 launch of the first-in-class diabetic nephropathy treatment is possible.
You may also be interested in...
Keryx Suffers Setback As Diabetic Nephropathy Candidate Fails Phase III Study
Firm falls back on mid-stage pipeline candidates in chronic kidney disease, kidney cancer.
Keryx Suffers Setback As Diabetic Nephropathy Candidate Fails Phase III Study
Firm falls back on mid-stage pipeline candidates in chronic kidney disease, kidney cancer.
Keryx Licenses Japanese Rights For Zerenex To Japan Tobacco In $100 Million Deal
Keryx Biopharmaceuticals got a major boost Sept. 26 in its effort to bring the Phase II hyperphosphatemia candidate Zerenex to the worldwide market by signing a licensing agreement potentially worth up to $100 million with Japan Tobacco and its subsidiary, Torii Pharmaceutical